Cloud-Based Mapping for Personalized Ablation

Atrial Fibrillation Clinical Trial

Official title:

Cloud-Based Mapping for Personalized Ablation

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04127123
• Other study ID #: 49800
• Secondary ID: 49800
• Status: Withdrawn
• Start date: July 3, 2019
• Est. completion date: January 11, 2021

Study information

• Verified date: May 2021
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Atrial fibrillation is a serious public health issue that affects over 5 million Americans in whom it may cause skipped beats, dizziness, stroke and even death. This study seeks to improve our understanding of the causes of atrial fibrillation and to design new and more effective therapy for this heart rhythm disorder.

Description:

This project will focus on the development of a novel paradigm for electrophysiologic data analysis and interpretation using cloud-based computing resources and mobile technology. Currently, electrophysiologic data gathered during a procedure is analyzed by the operator using multiple separate desk-based computer systems in the electrophysiology laboratory. The investigators propose that advances in cloud-based computing resources and network connectivity should apply a mobile paradigm to apply to invasive electrophysiologic procedures.

This project will provide proof-of-concept that open-access software the investigators have developed and made available online could be used, via a mobile phone interface, to identify sites in the heart where therapy is effective. At no time will patient therapy be guided by this system. The investigators will pursue therapy using only clinical means. In parallel, a double-blinded team will analyze data in real time using our online software visualized on a smartphone. Only when the case is concluded will the data be unblinded, to determine if the mobile system was accurate in real time.

Thus, development and testing of the cloud-based computing system is designed only to establish feasibility of the paradigm, followed by improvement of computational modeling algorithms. The data that is collected will add to the investigators' existing unique catalogue of multimodal (structural, clinical, and electrophysiologic) data.

The importance of this novel paradigm is to move from analyzing large volumes of data in isolation to creating a mobile platform, and to allow scalability to increase access, such as to underdeveloped medical centers.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 11, 2021
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

• men and women of any ethnicity

• aged 21-80 years

• undergoing ablation of atrial fibrillation at Stanford University

• failed or be intolerant of = 1 anti-arrhythmic drug or not willing to accept antiarrhythmic drug therapy.

Exclusion Criteria:

• active coronary ischemia or decompensated heart failure

• atrial or ventricular clot on trans-esophageal echocardiography

• pregnancy (to minimize fluoroscopic exposure)

• inability or unwillingness to provide informed consent

• rheumatic valve disease (because it results in a unique AF phenotype)

• thrombotic disease or venous filters

• significantly reduced kidney function

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Atrial Fibrillation

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mapping Accuracy	Location of driver regions for AF	During Procedure (Electrophysiology Study and Ablation)
Primary	Termination of atrial fibrillation	Does ablation at any driver region lead to AF termination	During Procedure (Electrophysiology Study and Ablation)